Ribo's RBD1016 Receives EMA Orphan Drug Designation for HDV Treatment Following the recent EMA Orphan Drug Designation, Ribo advances its siRNA therapeutic RBD1016 for treating Hepatitis Delta Virus (HDV) infection.

Ribo's RBD1016 Receives EMA Orphan Drug Designation for HDV Treatment #None #Ribo_Life_Science #RBD1016 #Hepatitis_Virus